298 patents
Page 13 of 15
Utility
Heterocyclic Compounds As Immunomodulators
3 Jun 20
Zhenwu Li, Liangxing Wu, Wenqing Yao
Filed: 3 Feb 20
Utility
Pyrazolopyrimidine Compounds and Uses Thereof
3 Jun 20
Oleg Vechorkin, Kai Liu, Jun Pan, Alexander Sokolsky, Hai Fen Ye, Qinda Ye, Wenqing Yao, Joshua Hummel
Filed: 2 Oct 19
Utility
Thiazolecarboxamides and Pyridinecarboxamide Compounds Useful As Pim Kinase Inhibitors
20 May 20
The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use.
Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
Filed: 14 Nov 19
Utility
Heterocyclic Derivatives As PI3K Inhibitors
13 May 20
Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
Filed: 11 Nov 19
Utility
Substituted Heterocyclic Derivatives As PI3K Inhibitors
13 May 20
Stacey Shepard, Andrew P. Combs
Filed: 11 Nov 19
Utility
Heterocyclic Derivatives As PI3K Inhibitors
13 May 20
Stacey Shepard, Yanran Ai, Andrew P. Combs, Artem Shvartsbart
Filed: 11 Nov 19
Utility
Pyrrolotriazine Compounds As Tam Inhibitors
29 Apr 20
Yun-Long Li, Xiaozhao Wang, Chunhong He
Filed: 3 Sep 19
Utility
Tricyclic Heterocycles As Bet Protein Inhibitors
29 Apr 20
Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, JR., James D. Rodgers
Filed: 26 Sep 19
Utility
Combination Therapy for Treatment of Hematological Diseases
29 Apr 20
The present application relates to treatment of a hematological disease selected from leukemia, lymphoma, and multiple myeloma in a patient in need thereof, comprising administering to the patient: (a) a therapeutically effective amount of a selective JAK1 inhibitor; (b) a therapeutically effective amount of an immunomodulatory agent, and (c) a therapeutically effective amount of a steroid.
Albert Assad
Filed: 30 Oct 19
Utility
Pyrimidinones As PI3K Inhibitors
22 Apr 20
The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
Filed: 19 Aug 19
Utility
DIHYDROPYRIDO[2,3-D]PYRIMIDINONE Compounds As CDK2 Inhibitors
15 Apr 20
The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 9 Oct 19
Utility
HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
1 Apr 20
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
Filed: 1 Oct 19
Utility
Janus Kinase Inhibitors for Treatment of Dry Eye and Other Eye Related Diseases
25 Mar 20
Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.
Paul A. Friedman, Jordan S. Fridman, Monica E. Luchi, William V. Williams
Filed: 17 Nov 19
Utility
Pyrazolopyrimidine Compounds and Uses Thereof
25 Mar 20
Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
Filed: 23 Sep 19
Utility
Bicyclic Heterocycles As FGFR Inhibitors
25 Mar 20
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
Filed: 9 Sep 19
Utility
ANTI-PD-1 Antibodies and Uses Thereof
25 Mar 20
Methods of treatment of cancer with antibodies and antibody fragments that bind to PD-1 are disclosed.
Mark Cornfeld, Naimish Bharat Pandya, Jon Marc Wigginton, Ross La Motte-Mohs, Bradley James Sumrow
Filed: 17 Jun 19
Utility
Pyrazolopyridine Compounds and Uses Thereof
18 Mar 20
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Jun Pan, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 19 Aug 19
Utility
Azetidinyl Phenyl, Pyridyl or Pyrazinyl Carboxamide Derivatives As Jak Inhibitors
11 Mar 20
The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Wenqing Yao, David M. Burns, Jincong Zhuo
Filed: 12 Nov 19
Utility
Salts of an LSD1 Inhibitor and Processes for Preparing the Same
4 Mar 20
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase.
Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
Filed: 28 Aug 19
Utility
Crystalline Forms of a Phosphoinositide 3-KINASE (PI3K) Inhibitor
4 Mar 20
The present invention relates to salts and crystalline forms of 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-methyl-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, and crystalline forms of 8-amino-N-(2-hydroxy-2-methylpropyl)-3-(2-(methyl-d3)-5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide, which are PI3K inhibitors useful in the treatment of cancer and other diseases.
Brent Douty, David M. Burns, Andrew P. Combs, Zhongjiang Jia, Daniel Levy, Eddy W. Yue
Filed: 3 Sep 19